Neurology:见于卡培他滨诱发脑白质病的短暂性缄默伴胼胝体压部病变

2019-03-30 zyx整理 神经科病例撷英拾粹

50岁女性,在卡培他滨(1250mg/m2,每天两次)治疗进展期胃癌第7天,出现反复发作性缄默。发作间期神经系统查体提示轻度左侧偏瘫和右侧巴氏征。

50岁女性,在卡培他滨(1250mg/m2,每天两次)治疗进展期癌第7天,出现反复发作性缄默。发作间期神经系统查体提示轻度左侧偏瘫和右侧巴氏征。脑CT,发作期脑电图,电解质,血氨,维生素B1和B12检测均无明显异常。脑MRI可见胼胝体压部和皮质脊髓束DWI和FLAIR上双侧对称高信号(图)。停用化疗药后2天症状好转。在耐药性癫痫行胼胝体切开术后和通常累及胼胝体纤维的中毒性白质脑病患者中已有短暂性缄默的报道。

(图:FLAIR可见胼胝体[A]和皮质脊髓束[B,箭]双侧对称高信号;DWI[C]和ADC[D]序列可见弥散受限,符合细胞毒性水肿,提示急性中毒性白质脑病)

原始出处:Nicoletti T, Spagni G, Luigetti M, Iorio R. Teaching NeuroImages: Transient mutism associated with splenium lesion in capecitabine-induced leukoencephalopathy. Neurology. 2019 Feb 26;92(9):e1000-e1001.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765774, encodeId=72541e657742b, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Oct 16 04:07:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000746, encodeId=87fb2000e4681, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Nov 24 16:07:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034259, encodeId=439c2034259d5, content=<a href='/topic/show?id=2ae18425852' target=_blank style='color:#2F92EE;'>#胼胝体压部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84258, encryptionId=2ae18425852, topicName=胼胝体压部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Jan 15 07:07:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764529, encodeId=8fe51e645297d, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Apr 29 10:07:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641348, encodeId=806b16413484e, content=<a href='/topic/show?id=70be8425665' target=_blank style='color:#2F92EE;'>#胼胝体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84256, encryptionId=70be8425665, topicName=胼胝体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67a222794165, createdName=12498c32m75暂无昵称, createdTime=Mon Jul 01 06:07:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293517, encodeId=b98b129351e04, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596783, encodeId=0efb1596e83a9, content=<a href='/topic/show?id=866184965c7' target=_blank style='color:#2F92EE;'>#脑白质病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84965, encryptionId=866184965c7, topicName=脑白质病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30ab18418561, createdName=天堂的云, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765774, encodeId=72541e657742b, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Oct 16 04:07:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000746, encodeId=87fb2000e4681, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Nov 24 16:07:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034259, encodeId=439c2034259d5, content=<a href='/topic/show?id=2ae18425852' target=_blank style='color:#2F92EE;'>#胼胝体压部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84258, encryptionId=2ae18425852, topicName=胼胝体压部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Jan 15 07:07:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764529, encodeId=8fe51e645297d, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Apr 29 10:07:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641348, encodeId=806b16413484e, content=<a href='/topic/show?id=70be8425665' target=_blank style='color:#2F92EE;'>#胼胝体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84256, encryptionId=70be8425665, topicName=胼胝体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67a222794165, createdName=12498c32m75暂无昵称, createdTime=Mon Jul 01 06:07:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293517, encodeId=b98b129351e04, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596783, encodeId=0efb1596e83a9, content=<a href='/topic/show?id=866184965c7' target=_blank style='color:#2F92EE;'>#脑白质病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84965, encryptionId=866184965c7, topicName=脑白质病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30ab18418561, createdName=天堂的云, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
    2019-11-24 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765774, encodeId=72541e657742b, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Oct 16 04:07:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000746, encodeId=87fb2000e4681, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Nov 24 16:07:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034259, encodeId=439c2034259d5, content=<a href='/topic/show?id=2ae18425852' target=_blank style='color:#2F92EE;'>#胼胝体压部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84258, encryptionId=2ae18425852, topicName=胼胝体压部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Jan 15 07:07:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764529, encodeId=8fe51e645297d, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Apr 29 10:07:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641348, encodeId=806b16413484e, content=<a href='/topic/show?id=70be8425665' target=_blank style='color:#2F92EE;'>#胼胝体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84256, encryptionId=70be8425665, topicName=胼胝体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67a222794165, createdName=12498c32m75暂无昵称, createdTime=Mon Jul 01 06:07:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293517, encodeId=b98b129351e04, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596783, encodeId=0efb1596e83a9, content=<a href='/topic/show?id=866184965c7' target=_blank style='color:#2F92EE;'>#脑白质病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84965, encryptionId=866184965c7, topicName=脑白质病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30ab18418561, createdName=天堂的云, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1765774, encodeId=72541e657742b, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Oct 16 04:07:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000746, encodeId=87fb2000e4681, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Nov 24 16:07:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034259, encodeId=439c2034259d5, content=<a href='/topic/show?id=2ae18425852' target=_blank style='color:#2F92EE;'>#胼胝体压部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84258, encryptionId=2ae18425852, topicName=胼胝体压部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Jan 15 07:07:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764529, encodeId=8fe51e645297d, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Apr 29 10:07:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641348, encodeId=806b16413484e, content=<a href='/topic/show?id=70be8425665' target=_blank style='color:#2F92EE;'>#胼胝体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84256, encryptionId=70be8425665, topicName=胼胝体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67a222794165, createdName=12498c32m75暂无昵称, createdTime=Mon Jul 01 06:07:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293517, encodeId=b98b129351e04, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596783, encodeId=0efb1596e83a9, content=<a href='/topic/show?id=866184965c7' target=_blank style='color:#2F92EE;'>#脑白质病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84965, encryptionId=866184965c7, topicName=脑白质病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30ab18418561, createdName=天堂的云, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1765774, encodeId=72541e657742b, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Oct 16 04:07:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000746, encodeId=87fb2000e4681, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Nov 24 16:07:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034259, encodeId=439c2034259d5, content=<a href='/topic/show?id=2ae18425852' target=_blank style='color:#2F92EE;'>#胼胝体压部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84258, encryptionId=2ae18425852, topicName=胼胝体压部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Jan 15 07:07:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764529, encodeId=8fe51e645297d, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Apr 29 10:07:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641348, encodeId=806b16413484e, content=<a href='/topic/show?id=70be8425665' target=_blank style='color:#2F92EE;'>#胼胝体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84256, encryptionId=70be8425665, topicName=胼胝体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67a222794165, createdName=12498c32m75暂无昵称, createdTime=Mon Jul 01 06:07:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293517, encodeId=b98b129351e04, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596783, encodeId=0efb1596e83a9, content=<a href='/topic/show?id=866184965c7' target=_blank style='color:#2F92EE;'>#脑白质病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84965, encryptionId=866184965c7, topicName=脑白质病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30ab18418561, createdName=天堂的云, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1765774, encodeId=72541e657742b, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Oct 16 04:07:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000746, encodeId=87fb2000e4681, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Nov 24 16:07:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034259, encodeId=439c2034259d5, content=<a href='/topic/show?id=2ae18425852' target=_blank style='color:#2F92EE;'>#胼胝体压部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84258, encryptionId=2ae18425852, topicName=胼胝体压部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Jan 15 07:07:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764529, encodeId=8fe51e645297d, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Apr 29 10:07:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641348, encodeId=806b16413484e, content=<a href='/topic/show?id=70be8425665' target=_blank style='color:#2F92EE;'>#胼胝体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84256, encryptionId=70be8425665, topicName=胼胝体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67a222794165, createdName=12498c32m75暂无昵称, createdTime=Mon Jul 01 06:07:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293517, encodeId=b98b129351e04, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596783, encodeId=0efb1596e83a9, content=<a href='/topic/show?id=866184965c7' target=_blank style='color:#2F92EE;'>#脑白质病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84965, encryptionId=866184965c7, topicName=脑白质病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30ab18418561, createdName=天堂的云, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1765774, encodeId=72541e657742b, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Oct 16 04:07:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000746, encodeId=87fb2000e4681, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Nov 24 16:07:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034259, encodeId=439c2034259d5, content=<a href='/topic/show?id=2ae18425852' target=_blank style='color:#2F92EE;'>#胼胝体压部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84258, encryptionId=2ae18425852, topicName=胼胝体压部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Wed Jan 15 07:07:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764529, encodeId=8fe51e645297d, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Apr 29 10:07:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641348, encodeId=806b16413484e, content=<a href='/topic/show?id=70be8425665' target=_blank style='color:#2F92EE;'>#胼胝体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84256, encryptionId=70be8425665, topicName=胼胝体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67a222794165, createdName=12498c32m75暂无昵称, createdTime=Mon Jul 01 06:07:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293517, encodeId=b98b129351e04, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596783, encodeId=0efb1596e83a9, content=<a href='/topic/show?id=866184965c7' target=_blank style='color:#2F92EE;'>#脑白质病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84965, encryptionId=866184965c7, topicName=脑白质病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30ab18418561, createdName=天堂的云, createdTime=Mon Apr 01 11:07:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]

相关资讯

Lancet oncol:Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者,毒副作用可接受,且具有抗肿瘤效果

Tucatinib是一种有效的选择性口服HER2酪氨酸激酶抑制剂,有潜能为应用当前治疗方案仍病程进展的患者提供耐受良好的新的治疗方案。现有研究人员在美国开展一非随机化、开放性1b期临床试验,探究tucatinib联合卡培他滨或曲妥珠单抗应用于HER2阳性的乳腺癌患者时的推荐2期试验剂量、安全性、药代动力学和预活性。本研究招募年满18岁的HER2阳性的已应用过曲妥珠单抗、帕托珠单抗和曲妥单抗emta

EUR J Cancer:放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌:I / II期临床试验(SAKK 41/08)

局部晚期直肠癌的(LARCs)中,KRAS突变的发生频率约为40%,多靶点酪氨酸激酶抑制剂索拉非尼具有放射增敏作用并可能改善KRAS突变的LARC患者标准手术前放化疗的效果。 研究人员在一项I / II期临床试验(SAKK 41/08)中招募了包含有T3 / 4和/或N1 / 2M0 KRAS突变的LARC成年患者,在Ⅰ期临床中关于放疗联合卡培他滨和索拉非尼的剂量增加研究被直接用于II期研究

Lancet Gastroen Hepatol:III级结肠癌患者的辅助治疗——氟尿嘧啶S1vs卡培他滨

研究认为,对于日本III级结肠癌患者,卡培他滨辅助化疗仍是手术后标准治疗方案的首选,S1辅助化疗不被推荐

Lancet oncol:顺铂+卡培他滨联合化疗方案添加雷莫芦单抗并不能延长转移性胃癌患者的无进展存活期

VEGF和VEGF受体2 (VEGFR-2)介导的信号通路和血管生成参与胃癌的发病和进展。现研究人员对一线化疗中添加VEGFR-2拮抗剂单克隆抗体雷莫芦单抗是否可改善转移性胃癌或胃食管交界处腺癌患者的预后进行研究。研究人员在20个国际的126个中心开展一双盲的随机的安慰剂为对照的3期临床试验,招募年满18岁的HER2阴性的转移的胃癌或胃食管交界处腺癌患者,且要求ECOG表现状态0-1分,器官功能尚

JAMA Oncology:维生素B6不能预防卡培他滨引起的手足综合征

手足综合征是卡培他滨治疗常见的不良反应。JAMA Oncology近期发表了一篇文章,比较维生素B6和安慰剂组之间2级及以上的手足综合征发生率及发生时间,寻找手足综合征的预测因素。

EUR J Cancer:卡培他滨联合贝伐单抗在转移性结直肠癌维持治疗中的成本效益分析

成本效益分析是通过比较项目的全部成本和效益来评估项目价值的一种方法,成本效益分析作为一种经济决策方法已经用于医疗领域。就转移性结直肠癌患者的无进展生存期而言,在6个疗程的卡培他滨、奥沙利铂和贝伐单抗的一线治疗后,卡培他滨联合贝伐单抗(CAP-B)的维持治疗能够起到很好的疗效。这篇文献中,荷兰研究者们评估了CAP-B的成本效益。